Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 229-236

  Matthay, Katherine K ^a   DeSantes, Kenneth ^a   Hasegawa, Bruce ^a   Huberty, John ^a   Hattner, Robert S ^a   Ablin, Arthur ^a   Reynolds, C Patrick ^a   Seeger, Robert C ^a   Weinberg, Vivian K ^a   Price, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW RESCUE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; HUMAN; HYPOTHYROIDISM; INFANT; LEUKEMIA; MALE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031961810     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.229     Document Type: Article

References (26)

1. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996
2. 131I]iodobenzylguanidine. J Nucl Med 21:349-353, 1980
3. Sisson JC, Frager MS, Valk TW, et al: Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12-17, 1981
4. Hattner RS, Huberty JP, Engelstad BL, et al: Localization of m-iodo (131-I)benzylguanidine in neuroblastoma. Am J Roentgenol 143:373-374, 1984
5. Geatti O, Shapiro B, Sisson JC, et al: Iodine-131 metaiodobenzyl-guanidine for the location of neuroblastoma: Preliminary experience in ten cases. J Nucl Med 26:736-742, 1985
6. Sisson JC, Shapiro B, Beirwaltes WH: Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 25:198-206, 1984
7. Hartmann O, Lumbroso J, Lemerle J, et al: Therapeutic use of 131-I-metaiodobenzylguanidine in neuroblastoma: A phase II study in nine patients. Med Pediatr Oncol 15:205-211, 1987
8. Voute PA, Hoefnagel CA, Kraker J, et al: Radionuclide therapy of neural crest tumors. Med Pediatr Oncol 15:192-195, 1987
9. Klingebiel T, Berthold F, Treuner J, et al: Metaiodobenzylguanidine (MIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial. Med Pediatr Oncol 19:84-88, 1991
10. Hutchinson RJ, Sisson JC, Shapiro B, et al: 131-I-Metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol 15:226-232, 1992
11. 131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 35:244-247, 1991
12. Lashford LS, Lewis IJ, Fielding SL, et al: Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 10:1889-1896, 1992
13. Mastrangelo R, Lasorella A, Lavarone A, et al: Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis. Med Pediatr Oncol 21:411-415, 1993
14. DeKraker J, Hoefnagel CA, Caron H, et al: First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer 31A:600-602, 1995
15. Reynolds CP, Seeger RC, Vo DD, et al: Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 46:5882-5886, 1986
16. Mangner TJ, Wu JL, Wieland DM: Solid phase exchange radioiodination of aryl iodides. Facilitation by ammonium sulfate. J Org Chem 47:1484-1488, 1982
17. Moss TJ, Reynolds CP, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 324:219-226, 1991
18. Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988
19. Franks LM, Bollen A, Seeger RC, et al: Adult and adolescent neuroblastoma: Indolent course with poor survival. In press, Cancer 79:2028-2035, 1997.
20. Smith MA, Rubinstein L, Ungerleider RS: Therapy-related acute myeloid leukemia following treatment with epipodphyllotoxins: Estimating the risks. Med Pediatr Oncol 23:86-98, 1994
21. 131I-metaiodobenzylguanidine. Eur J Nucl Med 14:337-340, 1988
22. Guilloteau D, Chalon S, Baulieu JL, et al: Comparison of MiBG and monoamine uptake mechanisms. Pharmacological, animal and blood platelet studies. Eur J Nucl Med 14:341-344, 1988
23. Tygat BAM, Voute PA, Takeuchi S, et al: Metaiodobenzylguanidine uptake in platelets, megakaryoblastic leukaemia cell lines MKPL-1 and CHRF-288-11 and erythroleukaemic cell line HEL. Eur J Cancer 31A:603-606, 1995
24. Fielding SL, Flower MA, Ackery D, et al: Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: Results of a UK study. Eur J Nucl Med 18:308-316, 1991
25. 131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 35:228-231, 1991
26. 131]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 31A:252-256, 1995